NCT05551754 is a Phase 2/Phase 3 clinical trial of Ketone Supplement in Alcohol Drinking, sponsored by University of Pennsylvania.

Who is sponsoring NCT05551754?

NCT05551754 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT05551754?

Interventions in NCT05551754: Ketone Supplement, Alcohol Beverage.

What condition does NCT05551754 study?

NCT05551754 studies Alcohol Drinking.

Is NCT05551754 still recruiting?

NCT05551754 is currently active, enrolled. Last updated 16 January 2026.

Last reviewed 2026-01-16 · How we verify

NCT05551754

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Effects of Ketone Supplementation on Subjective and Objective Responses to Alcohol in Healthy Volunteers

Active, enrolled Phase 2/Phase 3 Last updated 16 January 2026

What this trial tests

Phase 2/Phase 3 trial testing Ketone Supplement in Alcohol Drinking in 10 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 October 2022

Primary endpoint
1 July 2026

1 July 2027

Quick facts

Lead sponsor	University of Pennsylvania
Phase	Phase 2/Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	10
Start date	20 October 2022
Primary completion	1 July 2026
Estimated completion	1 July 2027
Sites	1 location across United States

Drugs / interventions tested

Ketone Supplement
Alcohol Beverage — full drug profile →

Conditions studied

Alcohol Drinking — all drugs for Alcohol Drinking →

Sponsor

University of Pennsylvania

Who can join

Adults 21 to 50, any sex, with Alcohol Drinking. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Acute effects of breath/blood alcohol levels in response to ketone supplement verse placebo
Time frame: 4 hours
Change in breath/blood alcohol levels (grams per 210 Liters of breath) in response to ketone supplement verse placebo

Sponsor's own description

This is a single blinded, randomized trial to evaluate the immediate subjective and objective effects of alcohol after a dose ketone supplement compared to a placebo in 10 health volunteers. Subjects will complete 2 lab visits where they consume a dose of alcohol (based on weight), to bring their breath alcohol concentration to about 0.050%. Participants will randomly receive ketone supplement at one lab and the placebo at the next lab.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ketone Supplementation Dampens Subjective and Objective Responses to Alcohol: Evidence From a Preclinical Rat Study and a Randomized, Cross-Over Trial in Healthy Volunteers.
Li X, Shi Z, Todaro DR, Pond T, et al · · 2024 · cited 6× · PMID 38315678 · DOI 10.1093/ijnp/pyae009

Verify or expand the search:

Other trials of Ketone Supplement

Trials testing the same drug.

NCT06065657 — Effect of Nutritional Ketosis on Alcohol Metabolism · Phase 2, PHASE3 · active not recruiting
NCT05924295 — Variations in Ketone Metabolism · NA · recruiting

Other recruiting trials for Alcohol Drinking

Currently open trials in the same condition.

NCT07415707 — The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in N · NA · recruiting
NCT06815237 — Effects of Ketone Supplement and Alcohol on Brain Metabolism · Phase 2, PHASE3 · recruiting
NCT06994962 — Multi-Component Breath Alcohol Intervention Phase 3 · NA · recruiting
NCT05363878 — Development of a Culturally Grounded, Trauma-Informed Alcohol Intervention With a Reserve-Dwelling First Nation Group · NA · recruiting
NCT06309134 — The Healthy Families Bright Futures Program · NA · recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05551754 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 16 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05551754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing